Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663820 | 1.00 | SIGMAR1 (0.65) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| Methane SCHEMBL27919139 | 0.96 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL2480738 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL27595226 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL598156 | 0.94 | SIGMAR1 (0.62) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL598951 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL9299473 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL598910 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL6066140 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 | |
| SCHEMBL31490433 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CYP1A2CYP2A6BCHEHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441901-B2 | Quantum dot ink composition, and quantum dot electroluminescent device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-10-14 | — | — | US | claimed |
| CN-119758495-A | Insulating liquid, high-reliability liquid lens and application thereof | 上海酷聚科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-116606568-A | Quantum dot ink composition and quantum dot electroluminescent device | 三星电子株式会社 | 2023-08-18 | — | — | CN | claimed |
| US-20230257607-A1 | QUANTUM DOT INK COMPOSITION, AND QUANTUM DOT ELECTROLUMINESCENT DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-08-17 | — | — | US | claimed |
| US-4225747-A | Submarine electric power cables containing naphthalene based liquids | INDUSTRIE PIRELLI SOCIETA PER AZIONI (IT) | 1980-09-30 | — | — | US | claimed |
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | BRILLIANT LIGHT POWER, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12441901-B2 | Quantum dot ink composition, and quantum dot electroluminescent device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-10-14 | — | — | US | disclosed |
| CN-119758495-A | Insulating liquid, high-reliability liquid lens and application thereof | 上海酷聚科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119256643-A | Method for printing functional layers of electronic devices by combining inks | 默克专利有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240407250-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND ILLUMINATOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-118908981-A | Method for producing organometallic nucleophile and reaction method using organometallic nucleophile | 国立大学法人北海道大学 | 2024-11-08 | — | — | CN | disclosed |
| US-20240244957-A1 | FORMULATION OF AN ORGANIC FUNCTIONAL MATERIAL | Merck Patent KGaA (DE) | 2024-07-18 | — | — | US | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0733364-A1 | MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0731146-A2 | Cationic dyes, their production and use | Clariant Finance (BVI) Limited (VG) | 1996-09-11 | — | — | EP | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4039793-A | PRODUCTION OF MONOCHLORO- AND ARYL SUBSTITUTED SATURATED COMPOUNDS | UOP INC. (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540073-B2 | Heterogeneous hydrogen-catalyst solid fuel reaction mixture and reactor | SCO2, SOD1, HAO2 | SIGMAR1 2882/4885CYP1A2 1592/4885CYP2A6 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.